Xpovio for glioblastoma = pro
XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large Bcell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. At the recent annual meeting of the American Society of Clinical Oncology, researchers released data from the phase 2 glioblastoma trial, reporting that one-third of the 76 patients in the trial had not experienced a progression of their disease and that the median duration of response was 11 months. A phase II trial suggest that single-agent oral selinexor 80 mg once weekly warrants further study in GBM.
A.B. Lassman et al, CLINICAL TRIALS: TARGETED THERAPY| FEBRUARY 01 2022
A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clin Ca Resear Volume 28, Issue 3 1 February 2022
Xpovio Prescribing Information 2022